Samsung Bioepis And C-Bridge Capital Deal Eyes Up ‘Next-Generation’ Biosimilars In China

 
• By Dean Rudge
  
ChinaWallFlag
Samsung Bioepis continues to make inroads in China. • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products